A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine

NCT00505453 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Fluviral®

Sponsor

GlaxoSmithKline